Arcutis Biotherapeutics, Inc. (ARQT, Financial) revealed a leadership change with the upcoming retirement of its Chief Financial Officer, David Topper. In a planned succession move, Latha Vairavan, who currently holds the position of vice president and controller, will take over as the new CFO.
Topper will remain in his position until the company submits its first-quarter 10-Q report, which marks a significant financial filing. After this, he will continue to support the transition process, ensuring a smooth handover until his official departure on May 15.
This leadership change is a strategic step by Arcutis, aimed at maintaining continuity and stability within the executive team. Vairavan’s promotion reflects her strong background and understanding of Arcutis' operational and financial frameworks.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Arcutis Biotherapeutics Inc (ARQT, Financial) is $20.25 with a high estimate of $29.00 and a low estimate of $15.00. The average target implies an upside of 50.67% from the current price of $13.44. More detailed estimate data can be found on the Arcutis Biotherapeutics Inc (ARQT) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Arcutis Biotherapeutics Inc's (ARQT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
